Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
To estimate the clinical benefit of REGN2810 monotherapy for patients with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC) (Group 1) or with unresectable locally advanced CSCC (Group 2), as measured by overall response rate (ORR), according to central review.
Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms
This randomized clinical trial studies levocarnitine in treating patients with vismodegib-associated muscle spasms. Levocarnitine may decrease muscle spasms caused by vismodegib.
Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
This phase II trial studies how well pembrolizumab with or without vismodegib works in treating patients with skin basal cell cancer that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, blocks tumor growth in different ways by targeting certain cells. Vismodegib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether pembrolizumab is more effective alone or together with vismodegib in treating skinbasal cell cancer.
For more information on these studies please contact Clinical Research Coordinator, Alana Pague at 650-497-7499
Additional information available at www.clinicaltrials.gov